Clinically relevant gene fusions, including ALK, ROS1, RET, NTRK, FGFR3, and MET, occur in a small yet clinically meaningful subset of non-smoking NSCLC patients, underscoring the value of broad NGS-based molecular profiling. Here, ALK is linked to non-small cell lung carcinoma.